Lineage Cell Therapeutics Inc (LCTX) Stock Price, Quote & News

Latest News on LCTX

Jun 5, 2025, 8:00 AM EDT - 2 days ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

May 14, 2025, 8:00 AM EDT - 24 days ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 13, 2025, 5:53 PM EDT - 25 days ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 25 days ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 8:00 AM EDT - 26 days ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 1, 2025, 8:00 AM EDT - 5 weeks ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Apr 22, 2025, 8:00 AM EDT - 6 weeks ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Apr 21, 2025, 8:00 AM EDT - 6 weeks ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Mar 10, 2025, 8:16 PM EDT - 3 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:05 PM EDT - 3 months ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 3 months ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Feb 11, 2025, 8:00 AM EST - 4 months ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Feb 4, 2025, 8:00 AM EST - 4 months ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Jan 27, 2025, 4:05 PM EST - 4 months ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Jan 6, 2025, 8:00 AM EST - 5 months ago

Lineage Cell Therapeutics Issues Letter to Stockholders

Nov 21, 2024, 5:00 PM EST - 7 months ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Nov 20, 2024, 8:00 AM EST - 7 months ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Nov 14, 2024, 9:39 PM EST - 7 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 7 months ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 8:00 AM EST - 7 months ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Oct 14, 2024, 8:00 AM EDT - 8 months ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Sep 25, 2024, 8:00 AM EDT - 9 months ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Sep 18, 2024, 8:00 AM EDT - 9 months ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Aug 13, 2024, 8:00 AM EDT - 10 months ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 10, 2024, 12:03 AM EDT - 10 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 10 months ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 11 months ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 1 year ago

Lineage to Present at 2024 BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 10, 2024, 12:33 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Apr 29, 2024, 4:30 PM EDT - 1 year ago

Lineage Announces Changes to Board of Directors

Apr 23, 2024, 8:05 AM EDT - 1 year ago

Lineage Announces Appointment of New Board Member

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Mar 18, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Mar 13, 2024, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Mar 11, 2024, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

Mar 7, 2024, 10:22 PM EST - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024

Feb 13, 2024, 8:00 AM EST - 1 year ago

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

Feb 9, 2024, 9:15 AM EST - 1 year ago

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

Feb 6, 2024, 9:15 AM EST - 1 year ago

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

Jan 16, 2024, 8:00 AM EST - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

Dec 18, 2023, 8:00 AM EST - 1 year ago

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Nov 9, 2023, 11:37 PM EST - 1 year ago

Market Cap	150.03M
Revenue (ttm)	9.50M
Net Income (ttm)	-18.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-195.89%
Debt to Equity Ratio	0.00

Volume	874,900
Avg Vol	1,127,792
Day's Range	N/A - N/A
Shares Out	228.36M
Stochastic %K	29%
Beta	1.52
Analysts	Strong Sell
Price Target	$3.92